Tumor-stroma-immune in the Cypre Organoid Platform
Immune-and-stromal-integrated mechanism of action (MOA) analysis
Cytokine and functional immune profiling
Multi-omic readouts to support biomarker discovery
Application across bispecifics, IO agents, and tumor-specific assets
Cypre partnered with Charles River Labs to leverage their PDX tumor models listed here for Cypre 3D tumor organoids. Tumor cells have been genomically characterized for RNAseq and WES expression.
